Ybrain recently received the Translational Research Award at this year’s Neuroergonomics and NYC Neuromodulation Conferences (28 July–1 August, New York City, USA) for its transcranial direct current stimulation (tDCS) technology.
This recognition was conferred to researchers who made a significant contribution to the neuromodulation field, with only two out of dozens of renowned scholars of neuromodulation being awarded, a press release notes.
Ybrain’s award-winning tDCS technology—which is used in the company’s MINDD-STIM+ therapy—is designed for the treatment of major depressive disorder, and caters to patients that wish to manage use of antidepressants as a form of treatment.
“We hope that our ‘at-home electroceutical treatment’ will be used as the new neuromodulation technology to solve the mental health problems exacerbated by the COVID-19 pandemic,” said Kiwon Lee, CEO of Ybrain. “With the alleged increase in the patient population with depression in the USA, Ybrain’s new MINDD-STIM+ hopes to bring an electroceutical alternative to patients who are averse to using antidepressants, right from the comfort of their own home.”
According to Ybrain officials, treating major depressive disorder is the first step, with clinical trials for schizophrenia, dementia, stroke and Parkinson’s disease well underway. Ybrain is aiming to penetrate the American market, and has submitted and expects clearance of MINDD-STIM+ as de novo from the US Food and Drug Administration (FDA) early next year.